<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0703221823
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SHINGRIX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ADJUVANTED WITH AS01B
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        774.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GlaxoSmithKline Biologicals " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GlaxoSmithKline Biologicals 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BK
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Shingrix is a vaccine that helps to protect adults against herpes zoster (also called shingles) as well as shingles-related complications.</p><p>Shingrix can be given to:</p><ul><li>adults from the age of 50 years and above;</li><li>adults from the age of 18 years and above who are at increased risk of shingles.</li></ul><p><strong>What is shingles and what are the complications related to shingles?</strong></p><p>Shingles is caused by the same virus that causes chickenpox. After you have had chickenpox, the virus that caused it stays in your body in nerve cells. Sometimes, after many years, the virus becomes active again and causes shingles.</p><p>Shingles is a painful, blistering rash. It usually occurs in one part of the body and can last for several weeks. It may lead to complications such as long-lasting pain (post-herpetic neuralgia or PHN) and scarring. Less commonly, bacterial skin infections, weakness, muscle paralysis, loss of hearing or vision can occur.</p><p>&nbsp;</p><p><strong>What is post-herpetic neuralgia (PHN)?</strong></p><p>After the shingles blisters heal, pain can last for months or years and may be severe. This long-lasting nerve pain is called PHN.</p><p>PHN is the most common complication of shingles.</p><p><strong>How does the vaccine work?</strong></p><p>Shingrix helps your body to build its own protection against shingles and its complications.</p><p>As with all vaccines, Shingrix may not fully protect all people who are vaccinated.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Shingrix</strong><strong> should not be given</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-no-proof:
yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_099f2fd8-2275-4c1b-8138-32a39d96a34e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:13.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to any of the ingredients contained in Shingrix (listed in section 6). Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.</p><p><strong>Take special care with</strong><strong> Shingrix</strong></p><p>Your doctor needs to know before you receive Shingrix:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe infection with a high temperature. In these cases, the vaccination may be postponed until recovery. A minor infection such as a cold should not be a problem, but talk to your doctor first.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a bleeding problem or bruise easily.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting can occur following, or even before, any needle injection, therefore tell the doctor or nurse if you fainted with a previous injection.</p><p><strong>Using other medicines or vaccines</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, or have recently received any other vaccine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If Shingrix is given at the same time as another vaccine, a different injection site will be used for each vaccine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If Shingrix is given at the same time as 23-valent pneumococcal polysaccharide vaccine, you may be more likely to experience fever and/or shivering.&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>There is no information on the use of Shingrix in pregnant or breast-feeding women.</p><p><strong>Driving and using machines</strong></p><p>There is no information on whether Shingrix affects the ability to drive or use machines. However, do not drive or use machines if you are feeling unwell.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingrix is given as an injection of 0.5 ml into a muscle (usually in the upper arm).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will receive 2 injections 2 to 6 months apart. Based on your medical condition, your doctor may recommend that you receive the second injection 1 month after the first injection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be informed when you should come back for the second dose of Shingrix. Make sure you finish the complete vaccination course. This will maximise the protection offered by Shingrix.</p><p>Shingrix can be given if you have already been vaccinated with a live attenuated herpes zoster vaccine. Speak to your doctor for more information.</p><p>Shingrix cannot be used to prevent chickenpox.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Shingrix can cause side effects, although not everyone gets them.</p><p>The following side effects may occur after receiving Shingrix:</p><p><strong>Very common</strong> (these may occur with more than 1 in 10 doses of the vaccine):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach and digestive complaints (including nausea, vomiting, diarrhoea and/or stomach pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain (myalgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, redness and swelling at the injection site, tiredness, chills, fever</p><p>&nbsp;</p><p><strong>Common</strong> (these may occur with up to 1 in 10 doses of the vaccine):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site itching (pruritus), generally feeling unwell<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_797f052e-2e23-4d25-9ea6-2b4e6f0dfe86 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Uncommon</strong> (these may occur with up to 1 in 100 doses of the vaccine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain (arthralgia)<!--[if supportFields]><span lang=EN-GB style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
mso-ansi-language:EN-GB;mso-bidi-font-weight:bold'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_8d3fd181-fd88-4266-ab68-1b10efdceaf8
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB;mso-bidi-font-weight:
bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Rare </strong>(these may occur with up to 1 in 1,000 doses of the vaccine):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions including rash, hives (urticaria), swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing (angioedema)</p><p>&nbsp;</p><p>If any of the side effects gets serious contact your doctor straightaway. If you notice any side effects not listed in this leaflet, tell your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep this medicine out of the sight and reach of children.</li><li>Store in a refrigerator (2&deg;C &ndash; 8&deg;C)</li><li>Do not freeze</li><li>Store in the original package in order to protect from light</li><li>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</li><li><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1 dose (0.5 ml) contains 50 micrograms of glycoprotein E (gE) powder mixed with AS01<sub>B</sub> adjuvant suspension.<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_628eb68e-30d8-4d08-84aa-1f1a6f16c1f1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>gE is a protein present in the Varicella Zoster Virus. This protein is not infectious.</p><p>The adjuvant is composed of a plant extract (<em>Quillaja saponaria</em> Molina, fraction 21 (QS-21) (50 micrograms) and a bacterial extract (3-O-desacyl-4&rsquo;- monophosphoryl lipid A (MPL)) and is used to improve the body&rsquo;s response to the vaccine.<!--[if supportFields]><span lang=EN-GB style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_6f4201eb-a5f0-438c-9dbb-f5483eeca545 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>The other ingredients are:</p><p>&nbsp;</p><p><u>Powder</u><!--[if supportFields]><u><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";mso-fareast-language:JA;layout-grid-mode:line'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_bd01a5f5-226b-424e-8a1b-c5c9fc365036 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";mso-fareast-language:JA;layout-grid-mode:line'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>Sucrose, polysorbate 80, sodium dihydrogen phosphate dihydrate, dipotassium phosphate.</p><p>&nbsp;</p><p><u>Suspension</u></p><p>Dioleoyl phosphatidylcholine, cholesterol, sodium chloride, disodium phosphate anhydrous, potassium dihydrogen phosphate and water for injections.</p><p><strong>I</strong><strong>nstructions for use</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:13.0pt;
mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5109724b-93dc-4b5b-826e-9e5e53e57027 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:13.0pt;
mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>The following information is intended for medical or healthcare professionals only:</strong></p><p>The powder and suspension should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not reconstitute the vaccine.</p><p><strong>How to prepare Shingrix:</strong></p><p>Shingrix must be reconstituted prior to administration.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the entire contents of the vial containing the suspension into the syringe.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Add the entire contents of the syringe into the vial containing the powder.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Shake gently until the powder is completely dissolved.</p><p>The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.</p><p>The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not administer the vaccine.</p><p>&nbsp;</p><p>After reconstitution, the vaccine should be used promptly; if this is not possible, the vaccine should be stored in a refrigerator (2&deg;C &ndash; 8&deg;C). If not used within 6 hours it should be<strong><s> </s></strong>discarded.</p><p><strong>Before administration:</strong></p><p>1.&nbsp; Withdraw the entire contents of the vial containing the reconstituted vaccine into the syringe.</p><p>2.&nbsp; Change the needle so that you are using a new needle to administer the vaccine.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The powder is white. 
The suspension is an opalescent, colourless to pale brownish liquid.

One pack of Shingrix consists of: 
•	Powder for 1 dose in a vial
•	Suspension for 1 dose in a vial
Shingrix is available in a pack size of 1 vial of powder plus 1 vial of suspension or in a pack size of 10 vials of powder plus 10 vials of suspension

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Shingrix</strong> is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy; 2024 GlaxoSmithKline, all rights reserved.</p><p><strong>&nbsp;</strong></p><p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; KSA.</p><p>*member of GSK group of companies</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong><!--[if supportFields]><b><span lang=EN-GB style='font-size:12.0pt;
mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";mso-ansi-language:EN-GB;mso-fareast-language:JA;mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0c38494d-9055-4fa0-b7fa-7a1ce98d52ea \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB;mso-fareast-language:
JA;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>- GlaxoSmithKline Biologicals s.a.</p><p>Parc de la Noire Epine Avenue Fleming 20 1300 Wavre , BELGIUM</p><p>- Patheon Italia S.p.A.</p><p>Viale G.B. Stucchi, 110 , 20900 &ndash; Monza (MB) ,ITALY</p><p><strong>Release by</strong></p><p>GlaxoSmithKline Biologicals s.a</p><p>Rue de I&rsquo;Institut 89, B- 1330 Rixensart, Belgium</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email:&nbsp;gcc.medinfo@gsk.com<u>​</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:&nbsp;https://gskpro.com/en-sa/&nbsp;​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia​</p><p>To report any side effect(s):</p><p><strong>Kingdom of Saudi Arabia​</strong></p><p><strong>-National Pharmacovigilance centre (NPC)​</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting Hotline: 19999​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail:&nbsp;npc.drug@sfda.gov.sa<u>​</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:<u>&nbsp;</u>https://ade.sfda.gov.sa&nbsp;​</p><p>&nbsp;</p><p><strong>-GSK - Head Office, Jeddah​</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email:&nbsp;<u>s</u>audi.safety@gsk.com&nbsp;&nbsp;​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:&nbsp;https://gskpro.com/en-sa/<u>&nbsp;​</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: 08
Version Date: 24 February 2023

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">شينجركس هو لقاح يساعد في حماية البالغين من الإصابة بعدوى الهربس النطاقي (الحزام الناري) (يسمى أيضا داء شنجلس) ومضاعفات عدوى الهربس النطاقي (الحزام الناري).</p><p dir="RTL">يمكن أن يعطى لقاح شينجركس إلى</p><ul><li dir="RTL">البالغين الذين تتجاوز أعمارهم 50 عام.</li><li dir="RTL">البالغين الذين تتجاوز أعمارهم 18 ومعرضون للإصابة بعدوى الهربس النطاقي</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي عدوى الهربس النطاقي (الحزام الناري) وما هي مضاعفاتها.</strong></p><p dir="RTL">ينتج داء الهربس النطاقي (الحزام الناري) بسبب عدوى فيروسية بنفس الفيروس الذي يسبب داء جدري الماء. بعد إصابتك بجدري الماء يظل الفيروس المسبب له كامنا في الخلايا العصبية بجسدك. في بعض الأحيان قد ينشط الفيروس مرة أخرى بعد أعوام مسببا داء الهربس النطاقي (الحزام الناري).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يظهر داء الهربس النطاقي (الحزام الناري) على هيئة طفح جلدي متقرح مؤلم، وعادة ما يصيب جزء واحد من الجسم وتدوم الأعراض لعدة أسابيع. قد يسبب داء هربس النطاقي (الحزام الناري) مضاعفات كاستمرار الألم لفترة طويلة (الألم العصبي التالي لعدوى هربس) كما قد يترك بعض الندب. وفي قليل من الأحيان يسبب عدوى بكتيرية ثانوية بالجلد وضعف وشلل بالعضلات، كما يمكن أن يتسبب في فقدان السمع أو البصر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو الألم العصبي التالي لعدوى هربس ؟</strong></p><p dir="RTL">قد يستمر الألم لعدة شهور أو سنوات بعد تحسن الطفح الجلدي الناتج عن داء هربس النطاقي (الحزام الناري)&nbsp; وقد يكون شديدا. ويسمى هذا الألم الممتد بالألم العصبي التالي لعدوى هربس.</p><p dir="RTL">يعد الألم العصبي التالي لعدوى هربس هو أكثر مضاعفات داء هربس النطاقي (الحزام الناري) انتشارا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل اللقاح؟</strong></p><p dir="RTL">يساعد لقاح شينجركس الجسد على تكوين مناعة ضد داء هربس النطاقي (الحزام الناري)&nbsp; ومضاعفاته.</p><p dir="RTL">وكما الحال في جميع اللقاحات لا يعطي لقاح شينجركس حماية كاملة لجميع من يحصلوا عليه.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجب أن تتلقى لقاح شينجركس في الحالات التالية:</strong></p><ul><li dir="RTL">إذا كنت تعاني من حساسية تجاه أي من مكونات عقار شينجركس (المذكورة في الجزء 6) قد تشمل علامات الحساسية طفح واكلان بالجلد وضيق بالتنفس وتورم بالوجه واللسان.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرعاية الصحية الخاصة بتلقي لقاح شينجركس: </strong></p><p dir="RTL">يجب إبلاغ طبيبك&nbsp; قبل تلقي لقاح شينجركس:</p><ul><li dir="RTL">إذا كنت تعاني من عدوى شديدة تسبب ارتفاع درجات الحرارة. في هذه الحالة قد يتأجل إعطاء اللقاح حتى تُشفى. العدوى الطفيفة كالبرد قد لا تمثل مشكلة لكن يجب أن تتحدث مع طبيبك بخصوصها أولا.</li><li dir="RTL">إذا كنت تعاني من اضطرابات سيولة الدم وتصاب بكدمات بسهولة.</li><li dir="RTL">قد تصاب بالإغماء بعد أو أثناء أو حتى قبل الحقن، أخبر الطبيب أو الممرضة إذا كنت قد أصبت بإغماء بسبب الحقن قبل ذلك.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام الأدوية الأخرى واللقاحات: </strong></p><ul><li dir="RTL">اخبر الطبيب أو الصيدلي إذا كنت تتناول أو سبق وتناولت أي أدوية في وقت قريب بما في ذلك الأدوية المصروفة بلا وصفة طبية أو إذا كنت قد تلقيت أي لقاح أخر.</li><li dir="RTL">في حال استخدام لقاح شينجركس مع لقاح أخر في نفس الوقت، يجب استخدام موضعين منفصلين للحقن واحد لكل لقاح.</li><li dir="RTL">اذا تم اعطاء شينجركس فى نفس الوقت مع لقاح المكورات الرئوية عديدة السكاريد ، فقد تكون اكثرعرضة للاصابة بالحمى و/ او الرعشة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة: </strong></p><p dir="RTL">أطلب النصيحة من الطبيب أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">لا يوجد معلومات كافية بخصوص تناول لقاح شينجركس أثناء الحمل والرضاعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يوجد معلومات كافية بخصوص تأثير لقاح شينجركس على القيادة أو استخدام الآلات.</p><p dir="RTL">على أي حال لا تقود السيارة أو تستخدم الآلات إذا شعرت أنك لست بخير.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL">يعطى لقاح شينجركس على هيئة حقن بحجم 0,5 ملي لتر تحقن في العضل (بأعلى الذراع غالبا)</li><li dir="RTL">ستتلقى جرعتين من اللقاح بينهما فاصل زمني يتراوح من شهرين إلى ستة أشهر، وبناء على حالتك الصحية قد يوصي طبيبك المعالج بتناول جرعة ثانية بعد الجرعة الأولى بشهر واحد.</li><li dir="RTL">سيتم إخبارك بموعد العودة لتلقي الجرعة الثانية من لقاح شينجركس. تأكد من تلقي جرعات اللقاح كاملة لان ذلك سيوفر لك الحد الأقصى من الحماية التي يقدمها يعطى لقاح شينجركس.</li><li dir="RTL"><p dir="RTL">يمكن أن يعطى لقاح شينجركس لمن سبق وتلقى لقاح موهن ضد الهربس النطاقي (الحزام الناري). تحدث مع طبيبك للحصول على المزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يمكن استخدام لقاح شنيجركس لمنع عدوى جدري&nbsp; الماء.</p><p dir="RTL">&nbsp;</p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما الحال في جميع الأدوية قد يتسبب لقاح شينجركس في أعراض جانبية،&nbsp; إلا أنها لا تصيب جميع من يتلقوا اللقاح.</p><p dir="RTL">قد يسبب لقاح شينجركس الأعراض الجانبية التالية:</p><p dir="RTL"><strong>أعراض جانبية شائعة جدا</strong>: (تحدث بمعدل أكثر من واحد لكل 10 جرعات من اللقاح)</p><ul><li dir="RTL">صداع</li><li dir="RTL">أعراض خاصة بالمعدة والجهاز الهضمي (تشمل الغثيان والقيء والإسهال وألم المعدة).</li><li dir="RTL">ألم العضلات.</li><li dir="RTL">ألم واحمرار وتورم موضع الحقن وإجهاد ورجفان وحمى.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة :</strong> (تحدث بمعدل&nbsp; أقل&nbsp; مرة&nbsp; واحدة لكل 10 جرعات من اللقاح)</p><ul><li dir="RTL">حكة بموضع الحقن والشعور بالتعب العام.</li></ul><p dir="RTL"><strong>أعراض جانبية غير شائعة :</strong> (تحدث بمعدل&nbsp; أقل&nbsp; مرة&nbsp; واحدة لكل 100 جرعة من اللقاح)</p><ul><li dir="RTL">آلام المفاصل (ألم مفصلي)</li></ul><p dir="RTL"><strong>أعراض جانبية نادرة:</strong> (تحدث بمعدل أقل من مرة&nbsp; واحدة لكل 1000 جرعة من اللقاح)</p><ul><li dir="RTL">حساسية تشمل الطفح الجلدي وحكة (شرى) وتورم بالوجه واللسان والحلق مما قد يسبب صعوبة البلع أو التنفس (تورم وعائي)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">تواصل مع طبيبك إذا أصبت بأعراض جانبية خطيرة وإذا أصبت بأعراض جانبية غير المذكورة في النشرة، أخبر الطبيب أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL">أحفظ الدواء بعيدا عن نظر ومتناول الأطفال.</li><li dir="RTL">يتم تخزين اللقاح في الثلاجة بدرجة حرارة تتراوح بين 2&nbsp; و 8 درجة مئوية.</li><li dir="RTL">لا تجمده</li><li dir="RTL">قم بتخزين اللقاح في عبوته الأصلية لحمايته من الضوء</li><li dir="RTL">لا تستخدم الدواء بعد مرور فترة الصلاحية الموضحة على الملصق والعبوة الورقية بعد كلمة: EXP . تاريخ انتهاء الصلاحية يشير لأخر يوم في الشهر المذكور.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">لا تلقي بأي دواء في مصرف المياه أو قمامة المنزل. اسأل الصيدلي عن كيفية التخلص من الدواء الذي لا تحتاجه. حيث تساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات لقاح شينجركس: </strong></p><p dir="RTL">الجرعة الواحدة من اللقاح (0,5 ملي لتر) تحتوي على 50 مايكرو جرام من مسحوق جليكوبروتين أي&nbsp; مخلوط&nbsp; بمعلق&nbsp; AS01B.</p><p dir="RTL">&nbsp;</p><p dir="RTL">جليكوبروتين أي&nbsp; هو بروتين موجود في فيروس جدري الماء، وهو بروتين لا يسبب العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويتكون المحلول من مستخلصات نباتية (كولاجة صابونية مولينا، كسر 21 (QS-21) 50 مايكرو جرام ومستخلص بكتيريا (3-0-desacyl-4 ودهون أحادية الفسفور ( MPL) A وتستخدم لتحسين استجابة الجسم للقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">والمكونات الأخرى هي:</p><p dir="RTL"><u>مسحوق: </u></p><p dir="RTL">سكروز وبولي سوربات 80&nbsp; ونازع هيدروجين الصوديوم ثنائي هيدروجين الفوسفات، وفوسفات ثنائي البوتاسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>معلق:</u></p><p dir="RTL">داياوليل فوسفاتيديلكولين و كوليستيرول وكلوريد الصوديوم ودايصوديوم فوسفات انهيدروز وبوتاسيوم دايهيدروجين فوسفات وماء للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف </strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو لقاح شينجركس وما هي محتويات العبوة.</strong></p><p dir="RTL">المسحوق أبيض</p><p dir="RTL">والمعلق لامع بلا لون يميل الى البني الشاحب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي العبوة الواحدة من لقاح شينجركس على:</p><ul><li dir="RTL">مسحوق لجرعة واحدة في فيال</li><li dir="RTL">معلق لجرعة واحدة في فيال.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">لقاح شينجركس متاح على هيئة عبوة تحتوي على 1 فيال مسحوق و1 فيال معلق&nbsp; أو عبوة تحتوي على 10 فيال مسحوق و10 فيال معلق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام: </strong></p><p dir="RTL"><strong>المعلومات التالية موجهة للأطباء أو مقدمي الرعاية الصحية فقط.</strong></p><p dir="RTL">يجب فحص المسحوق والمعلق بالعين المجردة لاكتشاف أي جسم غريب أو تغير في المظهر. إذا لاحظت أي تغيير لا تخلط مكونات اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يمكن إعداد لقاح شينجركس:</strong></p><p dir="RTL">يجب إعادة خلط اللقاح قبل إعطائه.</p><p dir="RTL">1- قم بسحب جميع محتويات الفيال الخاص بالمعلق إلى المحقنة.</p><p dir="RTL">2- أضف جميع محتويات المحقنة إلى الفيال الخاص بالمسحوق.</p><p dir="RTL">3- رج المخلوط برفق حتى تمتزج المكونات جيدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اللقاح بعد الخلط&nbsp; لامع بلا لون يميل الى البني الشاحب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب فحص المسحوق والمعلق بالعين المجردة لاكتشاف أي جسم غريب و / أو تغير في المظهر. إذا لاحظت أي تغيير لا تحقن اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام اللقاح بعد خلط مكوناته مباشرة وإذا لم يكن ذلك ممكن يجب تخزين اللقاح في الثلاجة بدرجة حرارة تتراوح بين 2&nbsp; و 8 درجة مئوية إذا لم يستخدم اللقاء خلال 6 ساعات من خلط مكوناته يجب التخلص منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل الحقن: </strong></p><p dir="RTL">1- اسحب جميع مكونات الفيال الذي يحتوي اللقاح بعد خلط مكوناته إلى المحقنة.</p><p dir="RTL">2- قم بتغيير إبرة الحقن بحيث تستخدم إبرة جديدة لحقن اللقاح.</p><p dir="RTL">أي دواء غير مستخدم أو فضلات يجب التخلص منها طبقا للقواعد المحلية.</p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL"><strong>&nbsp;جلاكسو سميث كلاين &ndash; المكتب اﻟﺮﺋﯿﺴﻲ، ﺟﺪة</strong></p><ul><li dir="RTL">هاتف: +966-12-6536666</li><li dir="RTL">الجوال:&nbsp; +966-56-904-9882</li><li dir="RTL">البريد الإلكتروني: &nbsp;gcc.medinfo@gsk.com</li><li dir="RTL">الموقع الإلكتروني:&nbsp; https://gskpro.com/en-sa/</li><li dir="RTL">ص.ب رقم 55850 ، جدة 21544 ، المملكة العربية السعودية.</li></ul><p dir="RTL"><!--[if gte vml 1]><v:roundrect
 id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_6" o:spid="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:35.85pt;
 margin-top:16.35pt;width:454.9pt;height:265.35pt;z-index:251662336;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAjey708AIAADeWQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsXM1u20YQvhfoOyx4alHoh5IoWULk
xHGqIECaGFbyACuSklhTJLukZDunNrZTw+itL1C0SOM6KQw3CNL02Kcgr32BvkJnl6T4Y0eynZVi
uZQBmVwuR8uZ2W9+drg3bm4NdDRSia2ZRlMQ80UBqYZsKprRawqPH7VySwKyHWwoWDcNtSlsq7Zw
c/nTT27gRo9gq6/JCCgYdgM3hb7jWI1CwZb76gDbedNSDbjWNckAO3BKegWF4E2gPNALpWKxWhhg
zRCWI1J3sIPRkGiXIKWb8oaqrGJjhG0gqcuNeEswRl3+cMq4YYzuEqttrRE6cvnBaI0gTWkKwDkD
D4BFQiG4EHSD00Lqrl5EYKtLBrS/2e2iLZCAWBGLdUlA202hUhUrUkXy6albDpKhg1Sr1Upl+DEZ
epTL1Xo97CH3H06hIfe/nEIFBuoPCA5ig7QtOkRjdPqpq+FTr6syqElPVxto3RwaiqqgVZMYoFmo
OuZIeL9t3Qd52T5ngIV+O+NS1AX42tn8ylSApXjomExReHFr/Jy4YRHbuauaA0QPmgKhg6cPw34P
j+7bDn32nhJIFytfC6g70EHfR1hHYrVardHnA4pBZzgKadI7bVPXlJam6+yE9DqrOkFwa1NosU9w
c6KbbqDNplBakmoSG0bioh2nUWSfs2iwB2Gq2Fex8qWhsGMHa7p/DMPUDTZuO9BlZ6vN5Oxs3TaV
bTrcDvwHMRATGAMqBzjhPISvrm7C8GRdswTUN8mTdBvtBzMNrghoE1CiKdjfDDFRBaTfM+ymUBcr
FSDnsJOKVCvBCYlf6cSvYEMGUvB7DhGQf7LqwDncNLSI1uvDb4mMTYa5AorS1RxfHv7o6XPottN2
tnWVsYA9IzwyGmByn5GBg3V2gPUeoCD8DHFAPj5R3WhbMpOdJa/Jji86sVgDxgdsj/e4rXbDvo7t
9w272ZYcXV3pMrWCtrWw39KYILSy61STfJghlCiBMeswx2A+kFx7BYD5CQyyDLehTjjay2iK2u2C
voOiM/bo2NEM5GxbahfLMPdWsa51iCYgCxumDQ3FUrFVlOCb/lWKZfoNVzVH7rfwQNMpLkGD3MfE
VpniMLoqngFR2Y4RfaQNVBs9UDcBgQbYSIy4VKzCSCUYLx15+dSIRbBzyRED84HhlO/Osrfr7brP
3UP4fuH+hdx33jPk/uIduL8h92f3JTSeIPeV+8J7Bn2glaIByJeSYIJLSk81co/bc5IeX57gxuyl
uEI0rCdkdxtkV2HaFujcVG2Ly66REoZqKGuY4PXxZIqLQ4TJRIV1XaYEJ2ZGPGNK7SMo5dN1hFEE
/qcP/RmYzgJMASZ3vT342/V2KIDCqfvOPfGR0z99DQi77x6fAaWRJgamMJu9kw0vQGHEs6s/e2PO
0mQXKC73WbtAmRHNoZQVneCQVjKHNHCd+epN3KnxMdQ9AQT9g0EmwOVb75l3gJireuQdeE/dPxG0
UnR9Tf1Wby8E22Pa7P7K3NfPJss1PstmLVe+3FpEV/XB2upkccTjvlmLI4v7nOXPU+KILGnmfZwr
7D+f91GulOrUaIzzMPoI0i/QoEEe0YAUQi7scf4EjShxT9CkfRPIjw3bT8b5GxFy2jQjRJtbpuHE
MhPt7UHHjAe1EqQhROAgzSNV4b9UrKWC2kRCohTSXYWkCstTNIV/n74N8k/Tc0RhWPv+gAYia7FU
CQgmun2EUJi3JZhTlojZ2hfukfuGHiH3kDWceE+9Pd9G74Hh/d09nuJLxW3u7ATHm8eJxBBv4gkB
cplMcWeqcQmBTJ4VvJ8/wVxehnm2TEViHT4LYj95y2smrI2cj/eG8aGZzAxptBYxZ0P6/gW5yZDB
a1bPHir4TpY4EDN7eQhR7QEYSXbynCUJj6Bpn0a3F0VqNISlR6PHUvoJp+bUGmqrdXHfhy8j5hGw
cjGduNHXNWNjVdfkjaCwAlZjpxd/QIWDJqt3THk4AKferwAhKl1uNA27r1k2LLs2aCUFuaeIgTTG
K3CGJecVMuzdsrsKzvfMUd7GKeOSSkldzI2i0zbTgXPHIvFZm/aeIjt1tYJk3tM1M/ITyxmuc7Sc
GfnL11JQuw6Lf/uQoH6XGXk+tTX8oWgeRp5lteKWhPoQNlSQYkXNf5Cdn+xq8zYECZebN3H+oo1z
PLPdUNDGxSsGrkaOz3UP0Ona09mZbt7q3xnGUt65ICo4O+F9lsM/GQh4VEfNI2zjMc5Jsz4VOcVX
GWddWpGlPZxl9xVbn9+Bdfp9BF97kP94ibwd1noApab/fPtjuICwA8sLh77bdMKW8F9D5x9o8enx
qbLTCI+uViDGS+YJ08hpjkQ8u+4YfvVXKyeDNy8tmp/3xtc2xgHd+x4Keo687xoo7dCloP3iNpLv
oFPWkjfxBCLwcuvGOcgv6tVqTizlqlIZ3vqpptKPEXJcLbRdCB5HzMtgd/yezUcqEvkIsMsLyxPz
n6/ix+GWLU298osrUyhwtfF2JnzmjrPpN3ZSPI2HJ2F9TKaz8M7KxFfYFswzWAxNZR6BVM3Vi5Vc
fWmplAKDyKplLsHFah3/V9m0LBLzk4mJSGwmADBjlyArXeH6xnjCm+PuZSA7hdYpNyMdKme1RA3+
ApnHMmM5XUuEh4oG5UNd1dm+1bM38rI5SKlCZrjpPg+XiT8zw80gkAta0RdJYqtfl3nhI4uLpsVF
WTkK/61eFtNOhG8/jfO9YTkK2AiLmNRMFMApmFZ3mk5PzNZv4OUmL5rvPQ/H4ZRCFDI3IauWOb1x
1+JXumZuwlQ34U2e1l34L3NK0pJUROOyC1QSpUqFnfu1rZfb2mZC/EkzRNO3peKb3Ugt1fIyNPx9
g/jKTD5D6LkiNNu8Mf7m/tQX9MPdDsVKle1sCtLjtH9iGoaB8vRCwes6sziVQ4194b9/ymZWU+DE
1Si9FFY7gK5Gu64ObbVt0S1oocSWXaDbssIB3YW3kNrZmF0IdmKm2yfHz5f/AwAA//8DAFBLAwQU
AAYACAAAACEAkn2H4B0HAABJIAAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3
EL4X6H9Y7L2xZL1iI3JgyXLcxC9ESoocKYnaZcxdLkjKjm5FcuqlQIG06KEBeuuhKBqgARr00h9j
wEGb/ogOuS9SouIHXCAobAHG7uw3w+HM7Mzs8M7dZxH1jjEXhMVtv3qr4ns4HrExiYO2/2iw/dlt
3xMSxWNEWYzb/gwL/+7Gp5/cQesjSpIhQ3w8CHGEPRAUi3XU9kMpk/WVFTECMhK3WIJjeDZhPEIS
bnmwMuboBBaI6MpqpdJciRCJ/Q2QKJWgHoV/sRSKMKK8r8RgL0YRrH4wmZAR1tjxUVUhxEx0KfeO
EW37IHPMTgb4mfQ9ioSEB22/ov/8lY07K2g9Y6JyCa/Bt63/Mr6MYXy0qtfkwbBYtF5v1JubhXwN
oHIR12v1mr1mIU8D0GgEO011sWW2Vrv1DGuA0kuH7K3WVq1q4Q35tQWdNxvqZ+E1KJVfX8Bvb3fB
ihZeg1J8YwHf6Kx1tmz5GpTimwv4VmVzq96y5GtQSEl8tICuNJq1br7bAjJhdMcJX2vUt1urmfAS
BdFQRJdaYsJiuSzWIvSU8W0AKCBFksSenCV4gkYQk11EyZATb5cEIQRegmImgFxZrWxXavBf/er6
SnsUrWNkcCu9QBOxQFL6eGLESSLb/n2Q6huQs7dvT5+/OX3+++mLF6fPf83W1qIsvh0UBybf+5++
+efVl97fv/34/uW36dLzeGHi3/3y1bs//vyQeNhxaYqz716/e/P67Puv//r5pUP6JkdDEz4gERbe
Pj7xHrIINujQHw/55TgGISImx2YcCBQjtYpDfk+GFnp/hihy4DrYtuNjDqnGBbw3fWop3A/5VBKH
xAdhZAH3GKMdxp1WeKDWMsw8mMaBe3E+NXEPETp2rd1FseXl3jSBHEtcIrshttQ8pCiWKMAxlp56
xo4wduzuCSGWXffIiDPBJtJ7QrwOIk6TDMjQiqaSaYdE4JeZS0Hwt2Wbvcdeh1HXrrfwsY2EdwNR
h/IDTC0z3kNTiSKXyAGKqGnwXSRDl5L9GR+ZuJ6Q4OkAU+b1xlgIF88Bh/0aTn8Aacbt9j06i2wk
l+TIJXMXMWYit9hRN0RR4sL2SRya2M/FEYQo8g6ZdMH3mP2GqHvwA4qXuvsxwZa7z88GjyDDmiqV
AaKeTLnDl/cws+K3P6MThF2pZpNHVord5MQZHZ1pYIX2LsYUnaAxxt6jzx0adFhi2bxU+n4IWWUH
uwLrPrJjVd3HWGBPNzeLeXKXCCtk+zhgS/TZm80lnhmKI8SXSd4Hr5s270Gpi1wBcEBHRyZwn0C/
B/HiNMqBABlGcC+Vehgiq4Cpe+GO1xm3/HeRdwzey6eWGhd4L4EHX5oHErvJ80HbDBC1FigDZoCg
y3ClW2Cx3F+yqOKq2aZOvon90pZugO7IanoiEp/bAc31Po3/rveBDuPsh1eOl+16+h23YCtZXbLT
WZZMdub6m2W4+a6my/iYfPxNzRaaxocY6shixrrpaW56Gv9/39Mse59vOpll/cZNJ+NDh3HTyWTD
levpZMrmBfoaNfBIBz167BMtnfpMCKV9OaN4V+jBj4DvmfE2EBWfnm7iYgqYhHCpyhwsYOECjjSP
x5n8gsiwH6IEpkNVXwkJRCY6EF7CBAyNNNkpW+HpNNpj43TYWa2qwWZaWQWSJb3SKOgwqJIputkq
B3iFeK1toAetuQKK9zJKGIvZStQcSrRyojKSHuuC0RxK6J1dixZrDi1uK/G5qxa0ANUKr8AHtwef
6W2/UQcWYIJ5HDTnY+Wn1NW5d7Uzr9PTy4xpRQA02HkElJ5eU7ou3Z7aXRpqF/C0pYQRbrYS2jK6
wRMhfAZn0amoF1Hjsr5eK11qqadModeD0CrVaN3+kBZX9TXwzecGGpuZgsbeSdtv1hoQMiOUtP0J
DI3hMkogdoT65kI0gOOWkeTpC3+VzJJwIbeQCFOD66STZoOISMw9SqK2r7ZfuIHGOodo3aqrkBA+
WuXWIK18bMqB020n48kEj6TpdoOiLJ3eQoZPc4XzqWa/Olhxsim4ux+OT7whnfKHCEKs0aoqA46J
gLODamrNMYHDsCKRlfE3V5iytGueRukYSumIJiHKKoqZzFO4TuWFOvqusIFxl+0ZDGqYJCuEw0AV
WNOoVjUtqkaqw9Kqez6TspyRNMuaaWUVVTXdWcxaIS8Dc7a8WpE3tMpNDDnNrPBp6p5PuWt5rpvr
E4oqAQYv7OeouhcoCIZq5WKWakrjxTSscnZGtWtHvsFzVLtIkTCyfjMXO2e3okY4lwPilSo/8M1H
LZAmeV+pLe062N5DiTcMqm0fDpdhOPgMruB42gfaqqKtKhpcwZkzlIv0oLjtZxc5BZ6nlAJTyym1
HFPPKfWc0sgpjZzSzClN39MnqnCKrw5TfS8/MIUalh2wZr2Fffq/8S8AAAD//wMAUEsDBBQABgAI
AAAAIQAyohoqLAEAAMIDAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnht
bC5yZWxztJPNakIxEIX3hb7DZfYman8oYtRFW3DRTbEPMCRzc4P3JiGJom/fsa2gYFsE3QTyd86X
mZPxdNO11ZpSdsErGIg+VOR1MM5bBR+L194TVLmgN9gGTwq2lGE6ub0Zv1OLhS/lxsVcsYrPCppS
4kjKrBvqMIsQyfNOHVKHhafJyoh6iZbksN9/lOlQAyZHmtXcKEhzcwfVYhvZ+X/tUNdO03PQq458
OWEhG1ZKrfNLFsVkqSjo0LUljHBlnMhYU9nObF4KHbr9mbdg2P5lUyh5bEGe5hxemXP3/My1RUMi
1waFDWsGludRDq5M+VNNH7UwaWVnB6TngT5cErRwHGnvr0AI+bXyPQ4ER/S3rt5fEuNE+vZd5cjF
FHapk+R7f7ZVHv28yScAAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAA
CwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAjey708AIAADeWQAA
HwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQA
BgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAAAAAAAAAAAAAAB0LAABjbGlwYm9hcmQvdGhlbWUvdGhl
bWUxLnhtbFBLAQItABQABgAIAAAAIQAyohoqLAEAAMIDAAAqAAAAAAAAAAAAAAAAAHISAABjbGlw
Ym9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAA5hMA
AAAA
" strokeweight="2.25pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL><b><span lang=AR-SA style='font-size:13.0pt;
    line-height:107%;font-family:"Times New Roman",serif;color:black'>للإبلاغ عن
    أية آثار جانبية</span></b><span dir=LTR></span><b><span dir=LTR
    style='font-size:13.0pt;line-height:107%;font-family:"Times New Roman",serif;
    color:black'><span dir=LTR></span>:<o:p></o:p></span></b></p>
    <p class=MsoNormal dir=RTL><b><i><span lang=AR-SA style='font-size:13.0pt;
    line-height:107%;font-family:"Times New Roman",serif;color:black'>المملكة العربية
    السعودية</span></i></b><b><i><span dir=LTR style='font-size:13.0pt;
    line-height:107%;font-family:"Times New Roman",serif;color:black'><o:p></o:p></span></i></b></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in'><b><span dir=LTR
    style='font-size:13.0pt;line-height:107%;font-family:"Times New Roman",serif;
    color:black'>- </span></b><b><span lang=AR-SA style='font-size:14.0pt;
    line-height:107%;font-family:"Times New Roman",serif;color:black'>المركز الوطني
    للتيقظ والسلامة الدوائية</span></b><span dir=LTR></span><b><span
    lang=AR-SA dir=LTR style='font-size:14.0pt;line-height:107%;font-family:
    "Times New Roman",serif;color:black'><span dir=LTR></span> </span></b><span
    dir=RTL></span><b><span lang=AR-SA style='font-size:14.0pt;line-height:
    107%;font-family:"Times New Roman",serif;color:black'><span dir=RTL></span>(</span></b><b><span
    dir=LTR style='font-size:14.0pt;line-height:107%;font-family:"Times New Roman",serif;
    color:black'>NPC</span></b><span dir=RTL></span><b><span lang=AR-SA
    style='font-size:14.0pt;line-height:107%;font-family:"Times New Roman",serif;
    color:black'><span dir=RTL></span>)</span></b><b><span lang=AR-EG
    style='font-size:13.0pt;line-height:107%;font-family:"Times New Roman",serif;
    color:black;mso-bidi-language:AR-EG'><o:p></o:p></span></b></p>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='margin-bottom:0in;
    mso-add-space:auto;text-indent:-.25in;line-height:normal;mso-list:l1 level1 lfo2;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-family:"Times New Roman",serif;color:#202124'>الاتصال بالرقم
    الموحد</span><span lang=AR-SA style='font-family:"Times New Roman",serif;
    color:#202124;mso-bidi-language:AR'> </span><span lang=AR style='font-family:
    "Times New Roman",serif;color:#202124;mso-bidi-language:AR'>: </span><span
    dir=LTR></span><span dir=LTR style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:Calibri'><span dir=LTR></span><span
    style='mso-spacerun:yes'> </span>19999<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-bottom:0in;
    mso-add-space:auto;text-indent:-.25in;line-height:normal;mso-list:l1 level1 lfo2;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri;
    color:black'>البريد الإلكتروني: </span><a href="mailto:npc.drug@sfda.gov.sa"><span
    class=Hyperlink1><span dir=LTR style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:Calibri'>npc.drug@sfda.gov.sa</span></span></a><span
    dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
    Calibri;color:blue'> <o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-bottom:0in;
    mso-add-space:auto;text-indent:-.25in;mso-list:l1 level1 lfo2;mso-layout-grid-align:
    none;text-autospace:none'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:Calibri;color:black'>الموقع الإلكتروني: </span><a
    href="https://ade.sfda.gov.sa/"><span class=Hyperlink1><span dir=LTR
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri'>https://ade.sfda.gov.sa</span></span></a><span
    dir=LTR style='font-family:"Times New Roman",serif'> </span><span dir=LTR
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri;
    color:black'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:0in;
    margin-right:8.2pt;margin-bottom:0in;margin-left:0in;mso-add-space:auto;
    text-indent:-4.5pt;mso-list:l3 level1 lfo4;mso-layout-grid-align:none;
    text-autospace:none'><![if !supportLists]><span dir=RTL></span><span
    style='font-size:14.0pt;mso-bidi-font-size:13.0pt;line-height:115%;
    font-family:"Times New Roman",serif;color:black'><span style='mso-list:
    Ignore'>-<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span
    dir=RTL></span><span dir=RTL></span><span style='font-family:"Arial",sans-serif;
    mso-ascii-font-family:Calibri;mso-ascii-theme-font:minor-latin;mso-hansi-font-family:
    Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-bidi'><span
    dir=RTL></span><span style='mso-spacerun:yes'> </span></span><b><span
    lang=AR-SA style='font-size:13.0pt;line-height:115%;font-family:"Times New Roman",serif;
    mso-fareast-font-family:Calibri;color:black'>جلاكسو سميث كلاين – المكتب الرئيسي،
    جدة</span></b><span dir=LTR style='font-size:13.0pt;line-height:115%;
    font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri;
    color:black'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-bottom:0in;
    mso-add-space:auto;text-indent:-.25in;line-height:normal;mso-pagination:
    none;mso-list:l0 level1 lfo3;mso-layout-grid-align:none;text-autospace:
    none'><![if !supportLists]><span style='font-size:12.0pt;mso-bidi-font-size:
    11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-family:"Times New Roman",serif'>هاتف:</span><span dir=LTR></span><span
    lang=AR-SA dir=LTR style='font-family:"Times New Roman",serif'><span
    dir=LTR></span> </span><span dir=RTL></span><span lang=AR-SA
    style='font-family:"Times New Roman",serif'><span dir=RTL></span><span
    style='mso-spacerun:yes'> </span></span><span dir=LTR></span><span dir=LTR
    style='font-family:"Times New Roman",serif'><span dir=LTR></span>+966-12-6536666<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-bottom:0in;text-indent:
    -.25in;line-height:normal;mso-list:l0 level1 lfo3;text-autospace:none'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri'>الجوال</span><span
    dir=LTR></span><span dir=LTR style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:Calibri'><span dir=LTR></span>:</span><span
    dir=RTL></span><span lang=AR-SA style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:Calibri'><span dir=RTL></span><span
    style='mso-spacerun:yes'>  </span></span><span dir=LTR></span><span
    dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
    Calibri'><span dir=LTR></span>+966-56-904-9882<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-bottom:0in;text-indent:
    -.25in;line-height:normal;mso-list:l0 level1 lfo3;text-autospace:none'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri'>البريد
    الإلكتروني: </span><span dir=LTR></span><span class=Hyperlink1><span
    dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
    Calibri'><span dir=LTR></span><span style='mso-spacerun:yes'> </span>s</span></span><span
    dir=LTR><a href="mailto:audi.safety@gsk.com"><span class=Hyperlink1><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri'>audi.safety@gsk.com</span></span></a></span><span
    dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
    Calibri'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-bottom:0in;text-indent:
    -.25in;line-height:normal;mso-list:l0 level1 lfo3;text-autospace:none'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri'>الموقع
    الإلكتروني: </span><a href="https://gskpro.com/en-sa/"><span dir=LTR
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri;
    color:blue'>https://gskpro.com/en-sa</span><span dir=RTL></span><span
    lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
    Calibri;color:blue'><span dir=RTL></span>/</span></a><span dir=LTR
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-bottom:0in;text-indent:
    -.25in;line-height:normal;mso-pagination:none;mso-list:l0 level1 lfo3;
    text-autospace:none'><![if !supportLists]><b style='mso-ansi-font-weight:
    normal'><span style='font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></b><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:Calibri'>ص.ب رقم 55850 ، جدة 21544 ، المملكة
    العربية السعودية</span><span dir=LTR></span><span dir=LTR style='font-size:
    12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:Calibri'><span
    dir=LTR></span>.<b><o:p></o:p></b></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-bottom:0in;line-height:
    14.65pt;mso-line-height-rule:exactly;text-autospace:none'><span dir=LTR
    style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
    Calibri'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:roundrect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:797px"><tbody><tr><td style="width:20px">&nbsp;</td></tr><tr><td style="width:20px">&nbsp;</td><td style="width:756px"><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية</strong><strong>:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong><strong> </strong><strong>(</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالرقم الموحد : &nbsp;19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">- &nbsp;<strong>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: &nbsp;+966-12-6536666</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجوال:&nbsp; +966-56-904-9882</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: &nbsp;saudi.safety@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ص.ب رقم 55850 ، جدة 21544 ، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ھﺬا اﻟﻤﻨﺘﺞ دواء</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك، واستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلانى الذى صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فالطبيب والصيدلانى هما الخبيران بالدواء، وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بجميع الأدوية بعيداً عن متناول لأطفال.</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شينجركس علامة تجارية مملوكة أو مرخصة لمجموعة شركات .GSK</p><p dir="RTL"><strong>ﺣﻘوق اﻟطﺑﻊ &copy; ﻟﻌﺎم 2024 ﻣﺣﻔوظﺔ ﻟ </strong><strong>GlaxoSmithKline</strong><strong>. ﺟﻣﯾﻊ اﻟﺣﻘوق ﻣﺣﻔوظﺔ</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ﻣﺎﻟﻚ اﻟﺘﺴﻮﯾﻖ اﻟﻤﻌﺘﻤﺪ واﻟﺸﺮﻛﺔ اﻟﻤُﺼﻨﻌﺔ</strong></p><p dir="RTL"><strong>ﻣﺎﻟﻚ اﻟﺘﺴﻮﯾﻖ اﻟﻤﻌﺘﻤﺪ:</strong></p><p dir="RTL">.Glaxo Saudi Arabia Ltd* ﺟﺪة، اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ</p><p dir="RTL">اﻟﻌﻨﻮان: ص. ب. 22617 ﺟﺪة 21416 &ndash; اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ.</p><p dir="RTL">إحدى شركات GlaxoSmithKline.</p><p dir="RTL"><strong>اﻟﺸﺮﻛﺔ اﻟﻤُﺼﻨﻌﺔ: </strong></p><p dir="RTL">- GlaxoSmithKline Biologicals s.a.</p><p dir="RTL">Parc de la Noire Epine Avenue Fleming 20 1300 Wavre , BELGIUM</p><p dir="RTL">- Patheon Italia S.p.A.</p><p dir="RTL">Viale G.B. Stucchi, 110 , 20900 &ndash; Monza (MB) ,ITALY</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الشركة المٌصدرة:</strong></p><p dir="RTL">GlaxoSmithKline Biologicals s.a</p><p dir="RTL">Rue de I&rsquo;Institut 89, B- 1330 Rixensart, Belgium</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رﻗم اﻹﺻدار: GDS 08 
ﺗﺎرﯾﺦ اﻹﺻدار:  24 فبراير 2023

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Herpes zoster (HZ, or shingles) vaccine (non-live recombinant, AS01B adjuvanted)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shingrix
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and suspension for suspension for injection.
After reconstitution, 1 dose (0.5 ml) contains 50 micrograms of gE antigen1 adjuvanted with AS01B2.

1 Varicella Zoster Virus (VZV) glycoprotein E (gE) produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells 

2 The GlaxoSmithKline proprietary AS01B Adjuvant System is composed of the plant extract Quillaja saponaria Molina, fraction 21 (QS-21) (50 micrograms) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (50 micrograms)

The powder is white.
The suspension is an opalescent, colourless to pale brownish liquid.
Excipients 
It is mandatory for country product information to include both the complete list of excipients for all locally marketed presentations, and any locally imposed excipient warning statements.
Powder (gE antigen): 
Sucrose
Polysorbate 80
Sodium dihydrogen phosphate dihydrate
Dipotassium phosphate
 
Suspension (AS01B Adjuvant System):
Dioleoyl phosphatidylcholine
Cholesterol
Sodium chloride
Disodium phosphate anhydrous
Potassium dihydrogen phosphate
Water for injections

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Shingrix is indicated for the prevention of herpes zoster (HZ) and HZ-related complications, such as post-herpetic neuralgia (PHN), in:</p><ul><li>adults 50 years of age or older;</li><li>adults 18 years of age or older at increased risk of HZ.&nbsp;</li></ul><p>The use of Shingrix should be based on official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The immunisation schedules for Shingrix should be based on official recommendations.</p><p><strong>Posology</strong></p><p>The primary vaccination schedule consists of two doses of 0.5 ml each; an initial dose followed by a second dose 2 to 6 months later.</p><p>For subjects who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, and whom would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose (see Pharmacodynamic Effects).</p><p>The need for booster doses has not been established.</p><p>Shingrix can be given with the same schedule in individuals previously vaccinated with live attenuated HZ vaccine (see Pharmacodynamic Effects).</p><p>Shingrix is not indicated for prevention of primary varicella infection.</p><p><strong>Method of administration</strong></p><p>Shingrix is for intramuscular injection only, preferably in the deltoid muscle.</p><p>For instructions on reconstitution of the medicinal product before administration, see Use and Handling.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any component of the vaccine (see Formulation and Strength and Excipients).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Prior to immunisation</strong></p><p>It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.</p><p>As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.</p><p>As with other vaccines, vaccination with Shingrix should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.</p><p>As with any vaccine, a protective immune response may not be elicited in all vaccinees.<strong><s> </s></strong></p><p>In a post-marketing observational study in individuals aged 65 years or older, an increased risk of Guillain-Barr&eacute; syndrome (estimated 3 excess cases per million doses administered) was observed during the 42 days following vaccination with Shingrix. Available information is insufficient to determine a causal relationship with Shingrix.</p><p><strong>Precautions for use</strong></p><p><strong>Do not administer the vaccine intravascularly, intradermally or subcutaneously. </strong></p><p>Maladministration via the subcutaneous route may lead to an increase in transient local reactions.</p><p>As with other vaccines administered intramuscularly, Shingrix should be given with caution to individuals with thrombocytopenia or any coagulation disorder, since bleeding may occur following an intramuscular administration to these subjects.</p><p>Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use with other vaccines</u></p><p><strong>&nbsp;</strong></p><p>Shingrix can be given concomitantly with unadjuvanted<strong> </strong>seasonal influenza vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23), pneumococcal conjugate vaccine (PCV) ,reduced antigen diphtheria-tetanus-acellular pertussis vaccine (dTpa) or coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine (see Pharmacodynamic Effects).</p><p>&nbsp;</p><p>The adverse reactions of fever and shivering were more frequent when PPV23 vaccine was co-administered with Shingrix compared to when Shingrix was given alone (see <em>Undesirable effects</em>).</p><p>&nbsp;</p><p>If Shingrix is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.<!--[if supportFields]><span style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f376defe-ca3c-4dbf-ac7c-52917e70e25a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;text-transform:none;mso-ansi-language:EN-US;font-weight:normal'><span
style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>Animal studies indicate no effects of Shingrix on male or female fertility.</p><p><strong>Pregnancy</strong></p><p>There are no data on the use of Shingrix in pregnant women. Animal studies performed with Shingrix administered to female rats do not indicate any harmful effects with respect to pregnancy (see Non-clinical information).</p><p><strong>Lactation</strong></p><p>The effect on breast-fed infants of administration of Shingrix to their mothers has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Shingrix on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical trial data </strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:JA'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_585c2296-fe33-4f54-9bf7-7f99c4600a33 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:JA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>The safety profile presented below is based on a pooled analysis of more than 14,500 adults &ge; 50 years of age, who have received at least one dose of Shingrix. These data were generated in placebo-controlled clinical studies (conducted in Europe, North America, Latin America, Asia and Australia) where Shingrix was administered according to a 0, 2-month schedule.</p><p>&nbsp;</p><p>Additionally, in clinical studies, 1,587 subjects &ge; 18 years of age who are immunodeficient or immunosuppressed due to disease or therapy (referred to as immunocompromised (IC)), were vaccinated with at least 1 dose of Shingrix. The reported adverse reactions were consistent with those presented in the Table below.</p><p><strong>&nbsp;</strong></p><p>Adverse reactions reported are listed according to the following frequency:</p><p>&nbsp;</p><p>Very common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/100 to &lt;1/10</p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/1,000 to &lt;1/100</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10,000 to &lt;1/1,000</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1/10,000</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_bfac060f-24fe-4612-88d5-939cb051f808 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p></td><td><p><strong>Frequency</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_26ac4a2d-f930-46a1-b239-01394c68e74b \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p></td><td><p><strong>Adverse reactions</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_ea8fa2ff-2fcc-4549-96c6-d0cf1e17d3eb \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common<!--[if supportFields]><span lang=EN-GB
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
  major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_e1dc003b-5ea0-4ec0-8064-f84e3d93ec02 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>headache<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_8693d7b8-7c67-44bf-932b-938b8055dd9c \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_692dfa3c-1c20-4f48-8071-17c5abc85672 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td style="vertical-align:top"><p>Very common<!--[if supportFields]><span lang=EN-GB
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
  major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_567fe08b-e06a-42e3-aa96-77c6bf679912 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common<!--[if supportFields]><span lang=EN-GB
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
  major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_8254664d-6c9a-44d9-9ba1-fe966ce77730 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>myalgia<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_155561d0-e266-41d8-84ea-2ea3b630b1a2 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon<!--[if supportFields]><span lang=EN-GB
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
  major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_17aea0f8-0813-490a-80dd-87c47599d047 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>arthralgia<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_8b18d339-8651-473b-9c1c-659e49119f87 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions<!--[if supportFields]><span lang=EN-GB
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
  major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_e66c5550-c54d-4a3f-b6f1-409d375c9a89 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td style="vertical-align:top"><p>Very common<!--[if supportFields]><span lang=EN-GB
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
  major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_028ebbb3-bfaf-4a4b-ab8c-8320115472b5 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>injection site reactions (such as pain, redness, swelling), fatigue, chills, fever<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_0ea17ecc-d01e-4a3d-a15c-0224ce008b4c \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td style="vertical-align:top"><p>Common<!--[if supportFields]><span lang=EN-GB style='font-size:
  12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_cdb9bbcf-1f10-4596-9a4e-05f3eec51f92 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>injection site pruritus, malaise<!--[if supportFields]><span lang=FR-BE
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
  major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_80c87da5-d94c-4235-83f8-7dc388b6813b \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=FR-BE style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  FR-BE'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr></tbody></table><p>&nbsp;</p><p>Overall, there was a higher incidence of some adverse reactions in younger age groups. However, the overall frequency and&nbsp;severity of these events did not indicate a clinically meaningful different reactogenicity profile in the younger age strata. In IC adult studies, there was a higher incidence of pain at the injection site, fatigue, myalgia, headache, shivering and fever in subjects aged 18 to 49 years compared with those aged 50 years and older. In older adult studies, there was a higher incidence of pain and swelling at the injection site, fatigue, myalgia, headache, shivering, fever and gastrointestinal symptoms in subjects aged 50 to 69 years compared with those aged 70 years and older.</p><p>&nbsp;</p><p>In a clinical study where 119 subjects &sup3; 50 years of age were vaccinated with Shingrix following a 0, 6-month schedule, the safety profile was similar to that observed in subjects vaccinated with Shingrix following a 0, 2-month schedule.</p><p>In a clinical study including 865 adults &sup3; 50 years of age, fever and shivering were reported more frequently when PPV23 vaccine was co-administered with Shingrix (16% and 21%, respectively) compared to when Shingrix was given alone (7% for both adverse reactions).</p><p>&nbsp;</p><p><strong>Post-marketing data</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_63ad786f-281a-45f0-843d-2aa7b9a15d2f
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_35568886-fd5d-42f2-975c-d2df3b1f8993 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p></td><td><p><strong>Frequency</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_51ecf45c-c7fd-4392-8085-db3296894493 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p></td><td><p><strong>Adverse reactions</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_8b8f2db9-0057-4bb3-9391-e58841b0ea99 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:12.0pt;
  font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_47721b5c-2a46-460c-adcb-0b60523249c3 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";
  mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>hypersensitivity reactions including rash, urticaria, angioedema<!--[if supportFields]><span style='font-size:
  12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
  mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_4fc60dee-939e-4cc5-8ee3-f2bdecd3a284 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
  major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
  mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>For any information about this medicinal product, please contact: ​</strong></p><p><strong>GSK- Head Office, Jeddah​</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email:&nbsp;gcc.medinfo@gsk.com<u>​</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:&nbsp;https://gskpro.com/en-sa/&nbsp;​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia​</p><p dir="RTL">&nbsp;</p><p><strong>To report any side effect(s):​</strong></p><p><strong>Kingdom of Saudi Arabia​</strong></p><p><strong>-National Pharmacovigilance centre (NPC)​</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Reporting Hotline: 19999​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail:&nbsp;npc.drug@sfda.gov.sa<u>​</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:<u>&nbsp;</u>https://ade.sfda.gov.sa&nbsp;​</p><p>&nbsp;</p><p><strong>-GSK - Head Office, Jeddah​</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email:&nbsp;<u>s</u>audi.safety@gsk.com&nbsp;&nbsp;​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:&nbsp;https://gskpro.com/en-sa/<u>&nbsp;​</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Insufficient data are available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATC Code</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_341f5ad5-a79c-4cb8-ae1c-7a74f1d4b89e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Pharmacotherapeutic group: Varicella zoster vaccines, ATC code: J07BK03.</p><p><strong>Mechanism of Action</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c11eb144-77e2-45d3-8b62-6b11515bdafb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Shingrix is designed to induce antigen-specific cellular and humoral immune responses in individuals with pre-existing immunity against VZV.<!--[if supportFields]><span style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2b83a9e9-7a0a-4fc4-99bc-30a1fbd23a44 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Non-clinical data show that AS01<sub>B</sub> induces a local and transient activation of the innate immune system through specific molecular pathways. This facilitates the recruitment and activation of antigen presenting cells carrying gE-derived antigens in the draining lymph node, which in turn leads to the generation of gE-specific CD4+ T cells and antibodies. The adjuvant effect of AS01<sub>B</sub> is the result of interactions between MPL and QS-21 formulated in liposomes.<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_6c222211-cf56-4e24-a80b-56ed03c2a3a7
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Pharmacodynamic Effects</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_37f3e6d0-6198-411c-8179-1973f937a84e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Efficacy of Shingrix </strong></p><p><u>Efficacy against Herpes Zoster (HZ) and Post-Herpetic Neuralgia (PHN)</u><!--[if supportFields]><u><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_a73ab071-8fbb-4cb0-9dd3-c7ba2b08c138
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;color:black;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></u><![endif]--></p><p>Two phase III, placebo-controlled, observer-blind efficacy studies of Shingrix were conducted in adults &ge; 50 years with 2 doses administered 2 months apart:<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
JA'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1f47ba9e-bc8a-4ccc-a95d-63aaddf50223 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
JA'><span style='mso-element:field-end'></span></span><![endif]--></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zoster-006 (ZOE-50): total vaccinated cohort (TVC) of 15,405 subjects &ge; 50 years who received at least one dose of either Shingrix (N=7,695) or placebo (N=7,710).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zoster-022 (ZOE-70): TVC of 13,900 subjects &ge; 70 years who received at least one dose of either Shingrix (N=6,950) or placebo (N=6,950).</p><p>&nbsp;</p><p>Two phase III, placebo-controlled, observer-blind studies evaluating Shingrix efficacy were conducted in IC adults &ge; 18 years with 2 doses administered 1-2 months apart:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zoster-002: TVC of 1,846 autologous hematopoietic stem cell transplants (aHSCT) recipients who received at least one dose of either Shingrix (N=922) or placebo (N=924)<br />post-transplant.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zoster-039: TVC of 562 subjects with hematologic malignancies who received at least one dose of either Shingrix (N=283) or placebo (N=279) during a cancer therapy course or after the full cancer therapy course.</p><p>&nbsp;</p><p>Incidence of HZ and PHN cases as well as vaccine efficacy were evaluated in the modified Total Vaccinated Cohort (mTVC i.e. excluding subjects who did not receive the second dose of vaccine or who had a confirmed diagnosis of HZ within one month after the second dose).</p><p>&nbsp;</p><p>Shingrix significantly decreased the incidence of HZ and PHN compared with placebo in:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults &ge; 50 years (Zoster-006): 6 vs. 210 HZ cases and 0 vs. 18 PHN cases;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults &ge; 70 years (pooled analysis of Zoster-006 and Zoster-022): 25 vs. 284 HZ cases and 4 vs. 36 PHN cases;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults &ge; 18 years with aHSCT (Zoster-002): 49 vs. 135 HZ cases and 1 vs. 9 PHN cases;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults &ge; 18 years with hematologic malignancies (Zoster-039): 2 vs. 14 HZ cases (PHN was not assessed as study endpoint). Vaccine efficacy was calculated post-hoc.</p><p>&nbsp;</p><p>Vaccine efficacy results are presented in Table 1.</p><p><strong>&nbsp;</strong></p><p><strong>Table 1</strong>: Shingrix efficacy against HZ and PHN (mTVC)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:566px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Age (years)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>HZ </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>PHN </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Efficacy (%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Efficacy</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Zoster-006*</strong></p></td></tr><tr><td><p><strong>&ge; 50</strong></p></td><td><p>7,344</p></td><td><p>97.2</p></td><td><p>93.7; 99.0</p></td><td><p>7,340</p></td><td><p>100.0</p></td><td><p>77.1; 100.0</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; 50-59</strong></p></td><td><p>3,492</p></td><td><p>96.6</p></td><td><p>89.6; 99.4</p></td><td><p>3,491</p></td><td><p>100.0</p></td><td><p>40.8; 100.0</p></td></tr><tr><td><p><strong>&ge; 60</strong></p></td><td><p>3,852</p></td><td><p>97.6</p></td><td><p>92.7; 99.6</p></td><td><p>3,849</p></td><td><p>100.0</p></td><td><p>55.2; 100.0</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; 60-69</strong></p></td><td><p>2,141</p></td><td><p>97.4</p></td><td><p>90.1; 99.7</p></td><td><p>2,140</p></td><td><p>100.0<sup>&sect;</sup></p></td><td><p>&lt; 0; 100.0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Pooled Zoster-006 and Zoster-022**</strong></p></td></tr><tr><td><p><strong>&ge; 70</strong></p></td><td><p>8,250</p></td><td><p>91.3</p></td><td><p>86.8; 94.5</p></td><td><p>8,250</p></td><td><p>88.8</p></td><td><p>68.7; 97.1</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; 70-79</strong></p></td><td><p>6,468</p></td><td><p>91.3</p></td><td><p>86.0; 94.9</p></td><td><p>6,468</p></td><td><p>93.0</p></td><td><p>72.4; 99.2</p></td></tr><tr><td><p><strong>&ge; 80</strong></p></td><td><p>1,782</p></td><td><p>91.4</p></td><td><p>80.2; 97.0</p></td><td><p>1,782</p></td><td><p>71.2<sup>&sect;</sup></p></td><td><p>&lt; 0; 97.1</p></td></tr><tr><td colspan="7"><p><strong>Zoster-002*** (aHSCT recipients</strong><strong><sup>#</sup></strong><strong>)</strong></p></td></tr><tr><td><p><strong>&ge; 18</strong></p></td><td><p>870</p></td><td><p>68.2</p></td><td><p>55.5; 77.6</p></td><td><p>870</p></td><td><p>89.3</p></td><td><p>22.5; 99.8</p></td></tr><tr><td><p><strong>&nbsp;&nbsp; 18-49</strong></p></td><td><p>213</p></td><td><p>71.8</p></td><td><p>38.7; 88.3</p></td><td><p>213</p></td><td><p>100.0<sup>&sect;</sup></p></td><td><p>&lt; 0; 100.0</p></td></tr><tr><td><p><strong>&ge; 50</strong></p></td><td><p>657</p></td><td><p>67.3</p></td><td><p>52.6; 77.9</p></td><td><p>657</p></td><td><p>88.0</p></td><td><p>10.4; 99.8</p></td></tr><tr><td colspan="7"><p><strong>Zoster-039 (hematologic malignancy patients</strong><strong><sup>#</sup></strong><strong>)</strong></p></td></tr><tr><td><p><strong>&ge; 18</strong></p></td><td><p>259</p></td><td><p>87.2****</p></td><td><p>44.2; 98.6</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p>N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of evaluable subjects</p><p>CI&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Over a median follow-up period of 3.1 and 4.1 years for reporting HZ and PHN cases, respectively</p><p>**&nbsp;&nbsp;&nbsp;&nbsp; Over a median follow-up period of 4.0 years for reporting HZ and PHN cases</p><p>***&nbsp;&nbsp; Over a median follow-up period of 21 months for reporting HZ and PHN cases</p><p>**** VE calculation was performed post-hoc; median follow-up period of 11.1 months</p><p>#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antiviral prophylaxis in line with the local standard of care was permitted</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not statistically significant</p><p>Zoster-006 mTVC: N (Shingrix) = 7,344, N (Placebo) = 7,415</p><p>Pooled analysis of Zoster-006 and Zoster-022 mTVC: N (Shingrix) = 8,250, N (Placebo) = 8,346</p><p>Zoster-002 mTVC: N (Shingrix) = 870, N (Placebo) = 851</p><p>Zoster-039 mTVC: N (Shingrix) = 259, N (Placebo) = 256</p><p>&nbsp;</p><p>In the fourth year after vaccination, the efficacy against HZ was 93.1 % (95% CI: 81.2; 98.2) and 87.9% (95% CI: 73.3; 95.4) in subjects &ge; 50 years (Zoster-006) and subjects &ge; 70 years (pooled Zoster-006 and Zoster-022), respectively.</p><p>In Zoster-002, during a follow-up period starting 1 month post-dose 2 (i.e. corresponding to approximately 6 months after aHSCT) until 1 year after aHSCT, when the risk for HZ is the highest, the efficacy against HZ was 76.2% (95% CI: 61.1; 86.0).</p><p><u>Efficacy against other HZ-related complications</u><!--[if supportFields]><u><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_38892a30-711b-4070-9162-e237001c2218 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>The evaluated HZ-related complications (other than PHN) were: HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease including stroke, and visceral disease.</p><p>In the pooled analysis of Zoster-006 and Zoster-022, Shingrix significantly reduced HZ-related complications by 93.7% (95% CI: 59.5; 99.9) and 91.6% (95% CI: 43.3; 99.8) in subjects &ge; 50 years (1 vs. 16 cases) and subjects &ge; 70 years (1 vs. 12 cases), respectively.</p><p>In Zoster-002, Shingrix significantly reduced HZ-related complications by 77.8% (95% CI: 19.0; 96.0) in aHSCT recipients &ge; 18 years (3 vs 13 cases).</p><p>In addition, in Zoster-002, Shingrix significantly reduced HZ-related hospitalisations by 84.7% (95% CI: 32.1; 96.6) (2 vs. 13 cases).</p><p><u>Effect of Shingrix on HZ-associated pain</u><!--[if supportFields]><u><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ab12907c-5377-40e4-b379-e696f11fd444 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>In Zoster-022, Shingrix significantly reduced the use and the duration of HZ-associated pain medication by 39.6% (95% CI: 10.7; 64.8) and 49.3% (95% CI: 2.9; 73.5), respectively, in subjects &ge; 70 years with at least one confirmed HZ episode. The median duration of pain medication use was 30.0 and 38.0 days in the Shingrix and placebo group, respectively.</p><p>Overall there was a general trend towards less severe HZ-associated pain in subjects vaccinated with Shingrix compared to placebo.</p><p>In Zoster-002, Shingrix significantly reduced the duration of severe &lsquo;worst&rsquo; HZ-associated pain by 38.5% (95% CI: 11.0; 57.6) in aHSCT recipients &ge; 18 years with at least one confirmed HZ episode.</p><p><strong>Immunogenicity of Shingrix</strong></p><p>An immunological correlate of protection has not been established; therefore the level of immune response that provides protection against HZ is unknown.</p><p>In adults &ge; 50 years, the immune responses to Shingrix were evaluated in a subset of subjects from the phase III efficacy studies Zoster-006 [humoral immunity and cell-mediated immunity (CMI)] and Zoster-022 (humoral immunity). The gE-specific immune responses (humoral and CMI) elicited by Shingrix at 1 month post-dose 2 are presented in Tables 2 and 3, respectively.</p><p>&nbsp;</p><p><strong>Table 2</strong>: Humoral immunogenicity of Shingrix in adults &ge; 50 years at 1 month post-dose 2 (ATP cohort for immunogenicity)<strong> </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><tbody><tr><td colspan="6"><p><strong>Anti-gE immune response^</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age group (years)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>VRR<sup>&sect;</sup> (%)</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMC</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Median fold increase of concentrations vs pre-vaccination (Q1; Q3)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong>Zoster-006</strong></p></td></tr><tr><td><p><strong>&ge; 50</strong></p></td><td><p>1,070</p></td><td><p>98.5</p><p>(97.6; 99.1)</p></td><td><p>52,376.6</p><p>(50,264.1; 54,577.9)</p></td><td><p>41.9</p><p>(20.8; 86.9)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong>Pooled Zoster-006 and Zoster-022</strong></p></td></tr><tr><td><p><strong>&ge; 70</strong></p></td><td><p>742</p></td><td><p>96.6</p><p>(95.1; 97.8)</p></td><td><p>49,691.5</p><p>(47,250.8; 52,258.2)</p></td><td><p>34.3</p><p>(16.7; 68.5)</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>ATP &nbsp;&nbsp; According-To-Protocol</p><p>^&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-gE immune response = anti-gE antibody levels, measured by anti-gE enzyme-linked immunosorbent assay (gE ELISA)</p><p>N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of evaluable subjects at the specified time point (for the GMC)</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaccine response rate (VRR) for anti-gE is defined as the percentage of subjects who have at least a 4-fold increase in the post-dose 2 anti-gE antibodies concentration as compared to the pre-vaccination anti-gE antibodies (subjects seropositive at baseline), or as compared to the anti-gE antibodies cut-off value for seropositivity (subjects seronegative at baseline)</p><p>CI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>GMC&nbsp; Geometric Mean Concentration</p><p>Q1; Q3&nbsp;&nbsp; First and third quartiles</p><p>&nbsp;</p><p>At 3 years post-dose 2, the median fold increase over baseline was 9.3 (Q1: 4.9; Q3: 19.5) in adults &ge; 50 years (Zoster-006) and 7.2 (Q1: 3.5; Q3: 14.5) in adults &ge; 70 years (pooled<br />Zoster-006 and Zoster-022).</p><p>&nbsp;</p><p><strong>Table 3: </strong>Cell-mediated immunogenicity of Shingrix in adults &ge; 50 years at 1 month post-dose 2<strong> </strong>(ATP<sup> </sup>cohort for immunogenicity)</p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td colspan="4"><p><strong>gE-specific CD4[2+] T cell response^</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age group (years)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>Median frequency</strong></p><p><strong>(Q1; Q3)</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>Median fold increase of frequency vs. pre-vaccination</strong></p><p><strong>(Q1; Q3)</strong></p></td></tr><tr><td colspan="4"><p><strong>Zoster-006</strong></p></td></tr><tr><td><p><strong>&ge; 50</strong></p></td><td><p>164</p></td><td><p>1,844.1</p><p>(1,253.6; 2,932.3)</p></td><td><p>24.6</p><p>(9.9; 744.2)</p></td></tr><tr><td><p><strong>&ge; 70*</strong></p></td><td><p>52</p></td><td><p>1,494.6</p><p>(922.9<strong>; </strong>2,067.1)</p></td><td><p>33.2</p><p>(10.0; 1,052.0)</p></td></tr></tbody></table><p>ATP &nbsp;&nbsp; According-To-Protocol</p><p>^&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gE-specific CD4[2+] T cell response = gE-specific CD4+ T cell activity, measured by intracellular cytokine staining (ICS) assay (CD4[2+] T cells = CD4+ T cells expressing at least 2 of 4 selected immune markers)</p><p>N &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of evaluable subjects at the specified time point for the median frequency</p><p>Q1; Q3&nbsp;&nbsp; First and third quartiles</p><p>*<sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>The gE-specific CD4[2+] data in the &ge;70 YOA group were only generated in Zoster-006 because CD4+ T cell activity was not assessed in Zoster-022</p><p>&nbsp;</p><p>At 3 years post-dose 2, in Zoster-006, the median fold increase over baseline was 7.9 (Q1: 2.7; Q3: 31.6) in adults &ge; 50 years and 7.3 (Q1: 1.7; Q3: 31.6) in adults &ge; 70 years.</p><p>&nbsp;</p><p>Data from a phase II, open-label, single group, follow-up clinical study in adults &sup3; 60 years (Zoster-024) indicate that the vaccine-induced immune response (humoral and CMI) persists up to Month 72 (approximately 6 years post-dose 1 i.e. 70 months post-dose 2), following a 0, 2-month schedule (N= 119).</p><p>The median anti-gE antibody concentration was greater than 7-fold above the baseline pre-vaccination median concentration. The median frequency of gE-specific CD4[2+] T cells was greater than 3.7-fold above baseline pre-vaccination median frequency.</p><p>&nbsp;</p><p>In IC adults &ge; 18 years, the humoral and CMI responses to Shingrix were evaluated in:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one phase I/II study: Zoster-015 (HIV infected subjects);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one phase II/III study: Zoster-028 (patients with solid tumors undergoing chemotherapy);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; three phase III studies: Zoster-002 (aHSCT recipients vaccinated post-transplant), Zoster-039 (patients with hematologic malignancies vaccinated during a cancer therapy course or after the full cancer therapy course) and Zoster-041 (renal transplant recipients on chronic immunosuppressive treatment at the time of vaccination).</p><p>&nbsp;</p><p>The gE-specific immune responses (humoral and CMI) elicited by Shingrix at 1 month post-dose 2 in all IC populations studied are presented in Tables 4 and 5, respectively.</p><p>&nbsp;</p><p><strong>Table 4: </strong>Humoral immunogenicity of Shingrix in IC adults &ge; 18 years at 1 month post-dose 2 (ATP cohort for immunogenicity)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Anti-gE immune response^</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>VRR<sup>&sect;</sup> (%)</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>GMC</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Median fold increase of concentrations vs pre-vaccination (Q1; Q3)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Zoster-002 </strong><strong>(aHSCT recipients)</strong></p></td></tr><tr><td><p>82</p></td><td><p>67.1</p><p>(55.8; 77.1)</p></td><td><p>12,753.2</p><p>(7,973.0; 20,399.4)</p></td><td><p>14.1</p><p>(1.7; 137.0)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Zoster-028 (solid tumor patients)</strong></p></td></tr><tr><td><p>87</p></td><td><p>86.2</p><p>(77.1; 92.7)</p></td><td><p>18,291.7</p><p>(14,432.1; 23,183.5)</p></td><td><p>21.5</p><p>(7.0; 45.2)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Zoster-039 </strong><strong>(hematologic malignancy patients)</strong></p></td></tr><tr><td><p>217</p></td><td><p>65.4</p><p>(58.7; 71.7)</p></td><td><p>13,445.6</p><p>(10,158.9; 17,795.6)</p></td><td><p>17.2</p><p>(1.4; 87.4)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Zoster-041 (renal transplant recipients)</strong></p></td></tr><tr><td><p>121</p></td><td><p>80.2</p><p>(71.9; 86.9)</p></td><td><p>19,163.8</p><p>(15,041.5; 24,416.0)</p></td><td><p>15.1</p><p>(6.1; 35.0)</p></td></tr><tr><td colspan="4"><p><strong>Zoster-015 (HIV infected subjects)</strong></p></td></tr><tr><td><p>53</p></td><td><p>98.1</p><p>(89.9; 100)</p></td><td><p>42,723.6</p><p>(31,233.0; 58,441.6)</p></td><td><p>40.9</p><p>(18.8; 93.0)</p></td></tr></tbody></table><p>ATP &nbsp;&nbsp; According-To-Protocol</p><p>^&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-gE immune response = anti-gE antibody levels, measured by anti-gE enzyme-linked immunosorbent assay (gE ELISA)</p><p>N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of evaluable subjects at the specified time point (for the GMC)</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaccine response rate (VRR) for anti-gE is defined as the percentage of subjects who have at least a 4-fold increase in the post-dose 2 anti-gE antibodies concentration as compared to the pre-vaccination anti-gE antibodies (subjects seropositive at baseline), or as compared to the anti-gE antibodies cut-off value for seropositivity (subjects seronegative at baseline)</p><p>CI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>GMC&nbsp; Geometric Mean Concentration</p><p>Q1; Q3&nbsp;&nbsp; First and third quartiles</p><p>&nbsp;</p><p><strong>Table 5: </strong>Cell-mediated immunogenicity of Shingrix in IC adults &ge; 18 years at 1 month post-dose 2<strong> </strong>(ATP<sup> </sup>cohort for immunogenicity)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>gE-specific CD4[2+] T cell response^</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>Median frequency</strong></p><p><strong>(Q1; Q3)</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>Median fold increase of frequency vs. pre-vaccination</strong></p><p><strong>(Q1; Q3)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Zoster-002 </strong><strong>(aHSCT recipients)</strong></p></td></tr><tr><td><p>51</p><p>&nbsp;</p></td><td><p>6,644.9</p><p>(1,438.3; 13,298.6)</p></td><td><p>109.0</p><p>(34.4; 2,716.4)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Zoster-028* (solid tumor patients)</strong></p></td></tr><tr><td><p>22</p></td><td><p>778.8</p><p>(393.1; 1,098.2)</p></td><td><p>4.9</p><p>(1.7; 33.0)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Zoster-039 </strong><strong>(hematologic malignancy patients)</strong></p></td></tr><tr><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>3,081.9</p><p>(1,766.2; 7,413.6)</p></td><td style="vertical-align:top"><p>45.9</p><p>(16.4; 2,221.9)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Zoster-041 (renal transplant recipients)</strong></p></td></tr><tr><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>2,149.0</p><p>(569.4; 3,695.1)</p></td><td style="vertical-align:top"><p>47.7</p><p>(14.7; 439.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Zoster-015 (HIV infected subjects)</strong></p></td></tr><tr><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>2,809.7</p><p>(1,554.5; 4,663.7)</p></td><td style="vertical-align:top"><p>23.4</p><p>(8.5; 604.1)</p></td></tr></tbody></table><p>ATP &nbsp;&nbsp; According-To-Protocol</p><p>^&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gE-specific CD4[2+] T cell response = gE-specific CD4+ T cell activity, measured by intracellular cytokine staining (ICS) assay (CD4[2+] T cells = CD4+ T cells expressing at least 2 of 4 selected immune markers)</p><p>N &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of evaluable subjects at the specified time point for the median frequency</p><p>Q1; Q3&nbsp;&nbsp; First and third quartiles</p><p>* Blood for CMI was only collected from the group of subjects that received the first dose of Shingrix 8-30 days before the start of a chemotherapy cycle (i.e. largest group of the study)</p><p>At 1 year post-dose 2, the median fold increase over baseline ranged from 2.7 to 6.5 in terms of anti-gE antibody concentration and from 2.0 to 43.6 in terms of gE-specific CD4[2+] T-cell frequencies (studies Zoster-002, Zoster-028, Zoster-039 and Zoster-041).</p><p>At 2 years post-dose 2, in Zoster-002, the median fold increase over baseline was 1.3 in terms of anti-gE antibody concentration and 50.9 in terms of gE-specific CD4[2+] T-cell frequencies.</p><p><u>Immunogenicity following concomitant vaccination</u></p><p>In five phase III, controlled, open-label clinical studies, adults &ge; 50 years of age were randomized to receive 2 doses of Shingrix 2 months apart administered either concomitantly at the first dose or non-concomitantly with unadjuvanted seasonal influenza vaccine (N=828; Zoster-004), PPV23 vaccine (N=865; Zoster-035), PCV13 vaccine (N=912; Zoster-059) , dTpa vaccine formulated with 0.3 milligrams Al<sup>3+ </sup>(N=830; Zoster-042) or monovalent COVID-19 mRNA-1273 50 micrograms booster vaccine (Original SARS-CoV-2 strain) (N=539; Zoster-091). The vaccine response rate (in terms of anti-gE antibodies) was 95.8% (95% CI: 93.3; 97.6), 98.3% (95% CI: 96.4; 99.3), 99.1% (95% CI: 97.6; 99.7) , 97.8% (95% CI: 95.8; 99.1) and 97.4% (95% CI: 94.4; 99.0) following co-administration of Shingrix with the influenza, PPV23, PCV13 , dTpa and COVID-19 mRNA-1273 booster vaccine respectively. The immune responses of the co-administered vaccines were unaffected, with the exception of lower geometric mean concentrations (GMCs) for one of the pertussis antigens (pertactin) when Shingrix is coadministered with the dTpa vaccine. However, these data do not suggest clinically relevant interference.</p><p><u>Immunogenicity in subjects with a history of HZ prior to vaccination</u></p><p>In a phase III, uncontrolled, open-label clinical study (Zoster-033), 96 adults &ge; 50 years of age, with a history of HZ, received 2 doses of Shingrix 2 months apart. The vaccine response rate (anti-gE antibodies) at 1 month post-vaccination was 90.2% (95% CI: 81.7; 95.7).</p><p><u>Immunogenicity in subjects receiving 2 doses of Shingrix 6 months apart</u></p><p>In a phase III, open-label clinical study (Zoster-026) where 238 subjects &ge; 50 years of age were equally randomised to receive 2 doses of Shingrix 2 or 6 months apart, the vaccine response rate (anti-gE antibodies) at 1 month post-vaccination following the 0, 6-month schedule was 96.5% (95% CI: 90.4; 99.2).</p><p>The humoral immune response (anti-gE antibodies concentration) following the 0, 6-month schedule was not inferior to the humoral immune response following the 0, 2-month schedule, as the 97.5% CI upper limit of the antibodies concentration ratio was below 1.50 [1.16 (97.5% CI: 0.98; 1.39)].</p><p><u>Immunogenicity in individuals previously vaccinated with live attenuated herpes zoster (HZ) vaccine</u></p><p>In a phase III, open-label, multicentre clinical study (Zoster-048), 430 adults &ge; 65 years of age with or without a previous history of vaccination with live attenuated HZ vaccine &ge; 5 years earlier were group-matched at a 1:1 ratio to receive 2 doses of Shingrix 2 months apart. The immune response to Shingrix was unaffected by prior vaccination with live attenuated HZ vaccine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evaluation of pharmacokinetic properties is not required for vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See Pharmacodynamic Effects.<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
JA'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_29927bf0-f179-4520-be94-e9a9ebf6a230 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
JA'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>NON-CLINICAL INFORMATION</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_26ac6913-89fe-4acb-820a-5bd395b9fa2a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Reproductive Toxicology</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4bff69d6-44eb-4c13-88b9-4148afc10c9d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Administration of VZV gE AS01<sub>B</sub> to female rats did not indicate any harmful effects with respect to fertility, pregnancy, embryo<strong>-</strong>foetal development, parturition or postnatal development.<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_cf0585de-51c1-4627-a085-196187a0c0d0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Treatment of male rats did not affect mating performance, fertility or early embryonic development.<!--[if supportFields]><span lang=EN-GB style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5413ece3-8a40-4078-b932-f9a5eed1c552 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Animal toxicology and/or pharmacology</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;layout-grid-mode:line'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_530cf3fc-0b91-4ed5-be56-68e991de0d13 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of acute and repeated dose toxicity, local tolerance and cardiovascular/respiratory safety pharmacology.</p><p><!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
text-transform:none;mso-fareast-language:JA;font-weight:normal'><span
style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder (gE antigen):</u><!--[if supportFields]><u><span lang=DE
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";mso-ansi-language:DE;mso-fareast-language:JA;layout-grid-mode:line'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_dd18919e-efcb-439b-a766-dd6743d583ab \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
lang=DE style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";mso-ansi-language:DE;mso-fareast-language:JA;layout-grid-mode:line'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>Sucrose</p><p>Polysorbate 80</p><p>Sodium dihydrogen phosphate dihydrate</p><p>Dipotassium phosphate</p><p>&nbsp;</p><p><u>Suspension (AS01<sub>B</sub> Adjuvant System):</u></p><p>Dioleoyl phosphatidylcholine</p><p>Cholesterol</p><p>Sodium chloride</p><p>Disodium phosphate anhydrous</p><p>Potassium dihydrogen phosphate</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
For shelf-life after reconstitution of the medicinal product, see Use and Handling.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after reconstitution of the medicinal product, see Use and Handling.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Powder for 1 dose in a vial (type I glass) with a stopper (butyl rubber)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Suspension for 1 dose in a vial (type I glass) with a stopper (butyl rubber).</p><p>&nbsp;</p><p>Shingrix is available in a pack size of 1 vial of powder plus 1 vial of suspension or in a pack size of 10 vials of powder plus 10 vials of suspension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The powder and suspension should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not reconstitute the vaccine.</p><p>&nbsp;</p><p><strong>How to prepare Shingrix:</strong></p><p>Shingrix must be reconstituted prior to administration.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the entire contents of the vial containing the suspension into the syringe.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add the entire contents of the syringe into the vial containing the powder.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake gently until the powder is completely dissolved.</p><p>The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.</p><p>The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not administer the vaccine.</p><p><strong>&nbsp;</strong></p><p>After reconstitution, the vaccine should be used promptly; if this is not possible, the vaccine should be stored in a refrigerator (2&deg;C &ndash; 8&deg;C). If not used within 6 hours it should be discarded.</p><p><strong>Before administration:</strong></p><p>1. Withdraw the entire contents of the vial containing the reconstituted vaccine into the syringe.</p><p>2. Change the needle so that you are using a new needle to administer the vaccine.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Shingrix is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy; 2024 GlaxoSmithKline group of companies. All rights reserved.</p><p><strong>&nbsp;</strong></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK- Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email:&nbsp;<u>s</u>audi.safety@gsk.com&nbsp;&nbsp;​</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:&nbsp;https://gskpro.com/en-sa/<u>&nbsp;​</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer by: 
- GlaxoSmithKline Biologicals s.a.
Parc de la Noire Epine Avenue Fleming 20 1300 Wavre , BELGIUM
- Patheon Italia S.p.A.
Viale G.B. Stucchi, 110 , 20900 – Monza (MB) ,ITALY
Release by:
GlaxoSmithKline Biologicals s.a 
Rue de I’Institut 89, B- 1330 Rixensart, Belgium
Marketing Authorization Holder: 
Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia 
Address: P.O. Box 22617 Jeddah 21416 – KSA.
*member of GSK group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS 08 / Date of issue:  24 February 2023
 [2024] GSK group of companies 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>